What were the key takeaways from Masimo’s earnings call?

What factors drove the changes in Masimo's revenue and profit?

What does Masimo do and what are its main business segments?

What is the revenue and EPS growth rate for Masimo year over year?

What is Masimo's gross profit margin?

What is Masimo's latest dividend and current dividend yield?

What were the key takeaways from Masimo's earnings call?

What guidance did Masimo's management provide for the next earnings period?

- **Revenue and Margin Strength**: Q3 revenue +8%, adjusted EPS +38% to $1.32, operating margin expands 450 bps to 27.1%.
- **Strategic Wins**: $124M incremental contracts (48% YoY), strongest Q3 contracting performance in company history.
- **Philips Expansion**: Targeting significant share gains in Philips' installed base, with potential for accelerated growth over next 5 years.
- **AI and Wearables**: Launching AI-enabled sensors for opioid monitoring and wearable pilots (e.g., Radius VSM) with 2026 launches.
- **Guidance Tightened**: 2025 revenue $1.510-$1.530B, EPS raised to $5.40-$5.55 (midpoint +$0.15), driven by margin expansion and buybacks.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue increased 8% year-over-year, driven by strong demand for innovative technologies. Adjusted EPS rose 38% to $1.32, with operating margin expanding 450 basis points to 27.1%.
- **Strategic Wins**: Secured $124 million in incremental contracts, a 48% year-over-year increase, marking the strongest Q3 contracting performance in company history.
- **Philips Partnership**: Expanded collaboration with Philips, targeting significant share gains in Philips' installed base, with potential for even greater growth over the next 5 years compared to the past 5 years.
- **AI and Monitoring Innovations**: Launched AI-enabled sensors for opioid-induced respiratory depression detection, aligning with CMS requirements for hospital reporting. Wearable technology pilots (e.g., Radius VSM) demonstrate cost savings and clinical benefits, with plans for broader launches in 2026.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP revenue $371 million (+8% YoY), operating cash flow $57 million. Tightened 2025 revenue guidance to $1.510-$1.530 billion, raising EPS guidance to $5.40-$5.55 (midpoint +$0.15), driven by margin expansion, share buybacks, and reduced interest expense.
- **Margin Expansion**: Gross margin 62.2%, operating margin 27.1% (vs. 22.6% last year). Excluding tariffs, operating margin would be 28.5%, reflecting strong cost control.
- **Capital Allocation**: Returned $350 million to shareholders via $2.4 million share buybacks. Proceeds from Sound United sale used to repay debt and optimize capital structure.

**【Q&A Key Highlights】**
- **Philips Share Growth**: CEO emphasized Masimo's underpenetration in Philips' installed base, with potential for accelerated share gains in advanced monitoring categories (e.g., capnography, hemodynamics).
- **Wearable Technology**: Pilots for Radius VSM, W1, and Philips-integrated wrist sensors show promise for telehealth and continuous monitoring, with full launches expected in 2026.
- **2026 Outlook**: CFO noted normalization of fiscal year timing, with focus on consumable growth and margin expansion. Q4 shipments of large international contracts will drive accelerated consumable revenue growth.
- **Tariff Impact**: CFO highlighted $5 million tariff-related cost increase, but operational improvements offset部分 margin pressure, with plans to mitigate future impacts.


Masimo Corporation (MASI) Q3 2025 Earnings Call Transcript

- **Revenue and Margin Beat**: Q2 revenue $370M, EPS $1.33 (+46%), with 600bps operating margin expansion.
- **Strategic Leadership Expansion**: 5 new executives hired to drive commercial excellence and innovation.
- **Tariff Mitigation Success**: Reduced FY25 tariff impact by 60% to $17-19M, with further 100bps margin improvement expected.
- **Growth Drivers**: Adjacent market expansion (capnography, brain monitoring), AI-enabled monitors, and wearables innovation.
- **Philips Partnership Strength**: Sensors in >50% of Philips monitors, with continued collaboration.

**【CEO Summary Section】**
- **Revenue Growth and Margin Expansion**: Q2 revenue of $370 million, EPS of $1.33, with 600 basis points of operating margin expansion. 
- **Leadership Expansion**: Hired 5 new executives (Chief Commercial Officer, Japan/APAC President, Chief Marketing Officer, Quality/Regulatory Lead, CIO) to drive commercial excellence and innovation.
- **Strategic Growth Waves**: 
  1. **Commercial Excellence**: Aligning U.S. sales force to leverage pulse oximetry leadership in adjacent markets (capnography, brain monitoring) with <20% share. 
  2. **Intelligent Monitoring**: Developing next-gen monitors with AI algorithms (e.g., atrial fibrillation detection via pulse oximetry). 
  3. **Wearables Innovation**: Piloting telemonitoring solutions for long-term growth.
- **Tariff Mitigation Success**: Reduced tariff impact by >50% through supply chain adjustments and exemption qualifications, with further medium-term measures in development.

**【CFO Financial Commentary】**
- **Q2 Financials**: 
  - Revenue: $370M (+7.4% constant currency)
  - Gross Margin: 62.9% (40bps YoY improvement)
  - Operating Margin: 27.5% (600bps YoY expansion)
  - EPS: $1.33 (+46% YoY)
- **Tariff Impact**: $2M in Q2, with updated FY25 guidance of $17-19M impact (vs. prior $33-37M). 
- **Updated FY25 Guidance**: 
  - Revenue: $1.505-1.535B (8-11% constant currency growth)
  - EPS: $5.20-5.45 (30-36% growth)
  - Operating Margin: 27.0-27.5% (130bps YoY improvement)
- **Cash Flow**: $62M operating cash flow, used to repay $38M debt and repurchase $14M stock.

**【Q&A Highlights】**
- **Guidance Inputs**: Strong consumables growth, capital sales in low single digits, FX benefits. 
- **Sales Force Alignment**: Early feedback positive, but impact expected in 2026. 
- **Philips Relationship**: Strong partnership continues, with Masimo sensors in >50% of Philips monitors. 
- **Tariff Progress**: 50% reduction in impact, with 100-110bps further improvement expected by end of FY25. 
- **Product Performance**: Hemodynamic monitoring (LiDCO) piloting, next-gen monitor launch in H2 2026. 
- **Cybersecurity Recovery**: Fully operational post-Q2 attack, with enhanced security measures.

Masimo Corporation (MASI) Q2 2025 Earnings Call Transcript

- **Q1 Strong Performance**: 10% healthcare revenue growth, 750bps margin expansion, 56% EPS increase.
- **Tariff Headwinds**: 210-250bps margin impact in FY25, but team executing mitigation plans.
- **Strategic Shifts**: Regional sales teams, AI-enabled sensors, and expanded monitoring categories drive future growth.
- **Sound United Sale**: Completes portfolio refocus; proceeds to be used for share buybacks.
- **Tariff Risk Management**: 5% of COGS from China drives disproportionate impact, but potential for rate reductions.


**【CEO Summary Section】**
- **Revenue Growth & Margins**: Q1 healthcare revenue of $371M (+10% constant currency), with 750bps operating margin expansion to 28.8%. Non-GAAP EPS rose 56% to $1.36.
- **Strategic Priorities**: 
  - Transitioning sales teams from product-focused to regionally aligned to leverage full portfolio.
  - Investing in AI-enabled sensors and monitors for acute/post-acute care.
  - Leveraging pulse ox leadership to expand in capnography, hemodynamics, and brain monitoring.
- **Tariff Impact**: 210-250bps margin dilution in FY25, with $33M-$37M cost of sales increase. Team focused on mitigation strategies.
- **Sound United Sale**: $218M loss from impairment, but positions Masimo to refocus on healthcare growth. Proceeds prioritized for share buybacks.

**【CFO Financial Commentary】**
- **Q1 Financials**: 
  - GAAP net loss $171M (due to Sound United), vs. $47M from continuing ops.
  - Non-GAAP EPS $1.36 vs. $0.86 prior year.
  - Gross margin 63.1% (+80bps YoY).
- **FY25 Guidance**: 
  - Revenue $1.5B-$1.53B (8%-11% growth).
  - Operating margin 28%-28.5% (excluding tariffs) vs. 25.5%-26.4% (including tariffs).
  - EPS $5.30-$5.60 (excluding tariffs) vs. $4.80-$5.15 (including tariffs).
- **Tariff Mitigation**: 
  - 25% of COGS from Mexico, 33% from Malaysia, 5% from China.
  - Potential 170% rate on Chinese raw materials/cables.
  - Impact increases Q2+ as tariffs flow through inventory.

**【Q&A Key Themes】**
- **Tender Contract Timing**: Q1 capital sales surged due to large tender, but consumables lagged. Normalized growth remains strong.
- **Tariff Mitigation Progress**: Near-term actions include supply chain shifts and pricing; long-term solutions depend on trade negotiations.
- **Hemodynamic Monitoring**: 2026 launch targeting mid-low acuity patients with integrated pulse ox and hemodynamics.
- **Cybersecurity Incident**: No patient data impacted; investigation ongoing, no guidance impact.
- **Share Repurchase Plan**: Proceeds from Sound United sale prioritized for buybacks, but timing depends on market conditions.


Masimo (MASI)-6 May 25-2025 Q1 Earnings call transcript

- **Record Q4 Performance**: $601M revenue, 22.4% operating margin, $1.80 EPS (44% YoY growth). FY24 healthcare revenue up 10% to $1.395B.
- **2025 Guidance**: Healthcare revenue $1.5B-$1.53B (8%-10% growth), EPS $5.10-$5.40 (22%-29% growth), 27.5%-28% margin.
- **Cost Efficiency**: $134M Q4 operating profit vs. $92M YoY, driven by $50M+ cash flow and 190bp healthcare margin expansion.
- **Strategic Shifts**: Consumer business divestiture underway; 25% of COGS at risk from tariffs, with Malaysia production ramping.
- **Growth Drivers**: $432M new contracts FY24, automation >20% growth, and >$100M pipeline for FY25.


**【CEO Opening Remarks】**
- **Mission Focus**: Emphasized Masimo's mission to improve patient outcomes through continuous monitoring, citing personal experience with daughter's near-fatal pneumonia. Highlighted the need for 24/7 patient monitoring beyond ICU settings.
- **Innovation & Talent**: Praised Masimo's R&D leadership and engineering talent, committing to programs that empower future leaders for scalable growth.
- **Strategic Momentum**: Noted $432M in incremental new contracts in FY24, positioning for future revenue visibility. Acknowledged Michelle Brennan's interim leadership and team's strong Q4 performance.

**【CFO Financial Highlights】**
- **Q4 2024 Results**: 
  - Total revenue: $601M (+9% YoY)
  - Healthcare revenue: $368M (+9% YoY)
  - Non-GAAP EPS: $1.80 (+44% YoY)
  - Operating margin: 22.4% (vs. 16.7% YoY)
- **FY24 Full Year**: 
  - Total revenue: $2.94B
  - Healthcare revenue: $1.395B (+10% YoY)
  - Non-GAAP EPS: $4.40 (+16% YoY)
- **2025 Guidance**: 
  - Healthcare revenue: $1.5B-$1.53B (8%-10% growth)
  - Non-GAAP EPS: $5.10-$5.40 (22%-29% growth)
  - Operating margin: 27.5%-28%
- **Cost Optimization**: Achieved $134M operating profit in Q4, driven by: 
  - 190bp healthcare gross margin improvement
  - $50M+ operating cash flow
  - Rationalization of $25M+ in corporate expenses

**【Key Strategic Updates】**
- **Consumer Business Sale**: Sound United (non-healthcare) classified as held-for-sale; FY25 guidance excludes its impact. 
- **Tariff Contingency**: 25% of healthcare COGS sourced from Mexico; contingency plans include shifting production to Malaysia.
- **Automation Growth**: Automation revenue grew >20% YoY, with >$100M pipeline for FY25.
- **Litigation Update**: Apple Watch exclusion order appeal pending; trade secret trial retrial scheduled.

**【Q&A Highlights】**
- **Operating Margin Expansion**: 570bp YoY improvement driven by: 
  - 1/3 from corporate cost cuts
  - 1/3 from consumer marketing spend reduction
  - 1/3 from healthcare portfolio rationalization
- **Market Share Assumptions**: FY25 guidance assumes low-single-digit census growth, aligned with FY24 contract pipeline.
- **Tariff Mitigation**: Flexibility to shift 25%+ of Mexico-sourced products to Malaysia; pricing strategies under evaluation.
- **Hemodynamics Opportunity**: Katie Szyman flagged unmet need for non-invasive hemodynamic monitoring, aligning with Masimo's R&D pipeline.


Actual											0.97	0.85	0.8	0.98	0.9	0.94	0.94	1.21	0.93	1.35	1	1.32	0.87	0.62	0.63	1.25	0.77	0.86	0.98	1.8	1.36	1.33	1.32
Forecast											0.9091	0.8109	0.6183	0.8596	0.875	0.9036	0.9119	1.1033	0.8998	1.2017	0.9244	1.1751	0.8347	0.6409	0.6055	0.9025	0.7038	0.765	0.8367	1.425	1.209	1.2227	1.2138
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+6.70%	+4.82%	+29.39%	+14.01%	+2.86%	+4.03%	+3.08%	+9.67%	+3.36%	+12.34%	+8.18%	+12.33%	+4.23%	-3.26%	+4.05%	+38.50%	+9.41%	+12.42%	+17.13%	+26.32%	+12.49%	+8.78%	+8.75%

MASI

MASI fundamentals

MASI Q3 2025 Earnings

Earnings Call

You can ask Aime

MASI

MASI fundamentals

MASI Q3 2025 Earnings

Earnings Call

MASI Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

MASI Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

MASI Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

MASI Earnings Call Summary for Q4/20244:30 PM on Feb 25, 2025

MASI Earnings Call Summary for Q3/20244:30 PM on Nov 5, 2024

You can ask Aime